JPWO2014157584A1 - Method for producing PEGylated bioactive substance labeled with [18F] F or fluorescent dye, and pharmacokinetic analysis thereof - Google Patents

Abstract

To provide a new technical means that enables non-invasive, highly sensitive and real-time quantification of spatiotemporal pharmacokinetics of drugs. The following formulas (Ia) and (Ib): embedded image wherein Ra1 is a divalent C1-C6 hydrocarbon group, Rb1-Rb10 is a hydrogen atom, Rc1 is a hydrogen atom, etc. X is divalent C1-C12 hydrocarbon group or -Rd1 (OCH2CH2) mRd2- (Rd1 is a divalent C1-C12 hydrocarbon group, etc., Rd2 is a divalent C1-C6 hydrocarbon group, etc., m is 1 kDa to 40 kDa in terms of molecular weight Y represents a monovalent group containing a biologically active substance, Z represents a monovalent group containing a fluorescent dye, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) [18F] F-labeled or fluorescently-labeled PEGylated bioactive substance represented by

Description

The present invention relates to a technique for PEGylating a bioactive substance and a technique for labeling with [ ¹⁸ F] F or a fluorescent dye for the analysis of the in vivo kinetics of the PEGylated bioactive substance.

  PEGylation is actively used in drug discovery research because long-chain polyethylene glycol (PEG, molecular weight of about 5,000 to 40,000) can be expected to maintain its efficacy and reduce side effects when bound to protein drugs. Already, PEGylated interferon α (a therapeutic agent for hepatitis C), PEGylated erythropoietin (a therapeutic agent for renal anemia), and the like are already on the market, and PEGylation of low-molecular drug candidate compounds has been actively conducted.

  Meanwhile, in 2008, the Ministry of Health, Labor and Welfare announced implementation guidance for the “Microdose Clinical Trial”. In order to improve the efficiency and safety of drug development, this is the dose that does not exceed 1 / 100th of the dose estimated to develop pharmacological effects in humans at the initial stage of clinical development, or 100 μg, whichever is less This is a test in which a dose of a test substance is administered to a healthy subject to obtain information on its pharmacokinetics. Therefore, a technique for quantifying the spatiotemporal pharmacokinetics of drugs in a non-invasive manner with high sensitivity and real time is required.

In order to meet the demands of such an era, the present inventors have created a novel PEG compound labeled with [ ¹⁸ F] F for several years and have been conducting application studies for pharmacokinetic analysis. That is, a novel PEG-containing low molecular weight compound (molecular weight 360) labeled with [ ¹⁸ F] F was created. As a result, a new technology for labeling liposomes and visualizing / quantifying pharmacokinetics in rats by positron tomography (PET) was developed (Patent Document 1, Non-Patent Document 1).

In addition, long chain PEG (molecular weight 2,000 and 10,000) labeled with [ ¹⁸ F] F was synthesized. Using this long-chain PEG, the pharmacokinetics of PEG itself in rats was successfully visualized / quantified using PET (Non-patent Document 2).

Patent No.4989241 (registered on May 11, 2012)

J. Med. Chem. 2007, 50, 6454-6457. Mol. Pharmaceutics 2011, 8, 302-308.

In the above technique, the step of introducing [ ¹⁸ F] F into PEG has been performed at 80 to 120 ° C., but when this heating condition is applied to a PEGylated peptide, the peptide is denatured. Furthermore, since [ ¹⁸ F] F has a half-life of 110 minutes, [ ¹⁸ F] F labeling needs to be performed quickly.

  The present invention has been made in view of the circumstances as described above, and is a novel technique that enables visualization / quantification of spatiotemporal pharmacokinetics of a PEGylated bioactive substance in a noninvasive manner with high sensitivity and in real time. The challenge is to provide technical means.

  In order to solve the above problems, the present invention is characterized by the following.

The [ ¹⁸ F] F-labeled PEGylated bioactive substance of the present invention has the following formula (Ia):

(In the formula, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 represents an amide group or a carbamic acid ester group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Divalent C _{1 to} C ₁₂ hydrocarbon group that may have, R ^d2 may be a divalent C _{1 to} C ₆ hydrocarbon group that may have an amide group, m is 1 kDa to 40 kDa in terms of molecular weight Y represents a monovalent group containing a biologically active substance, n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight, and R ^a1 represents _three nitrogen atoms of —N ₃ —. Are bonded to any one of the nitrogen atoms at both ends.

The method for producing a PEGylated bioactive substance labeled with [ ¹⁸ F] F of the present invention is a process for producing a PEGylated bioactive substance represented by the above formula (Ia), which is represented by the following formula (II-a): :

(Wherein, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon radical, n is an integer in the range of 1kDa~40kDa molecular weight basis.) And represented by ^[18 F] fluoro-PEG compound, the following formula (III):

(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 represents an amide group or a C _{1 to} C ₁₂ hydrocarbon group optionally having a carbamic acid ester group which may be formed together with an oxygen atom of (OCH ₂ CH ₂ ) _m ; R ^d2 is a divalent C _{1 to} C ₆ hydrocarbon group which may have an amide group, m represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight, and Y includes a biologically active substance. And a cyclic acetylene compound represented by the formula (Ia) under physiological conditions (in an aqueous solution, at room temperature and in the absence of a copper catalyst) (Huisgen reaction). It is characterized by synthesizing a PEGylated bioactive substance.

  The fluorescently labeled PEGylated bioactive substance of the present invention has the following formula (I-b):

(In the formula, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 represents an amide group or a carbamic acid ester group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Divalent C _{1 to} C ₁₂ hydrocarbon group that may have, R ^d2 may be a divalent C _{1 to} C ₆ hydrocarbon group that may have an amide group, m is 1 kDa to 40 kDa in terms of molecular weight Y represents a monovalent group containing a biologically active substance, Z represents a monovalent group containing a fluorescent dye, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight. ^a1 is represented by any one of the three nitrogen atoms of —N ₃ — bonded to one of both ends.

  The method for producing a fluorescently labeled PEGylated bioactive substance of the present invention is a process for producing a PEGylated bioactive substance of the above formula (I-b), which has the following formula (II-b):

(In the formula, Z represents a monovalent group containing a fluorescent dye, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) Fluorescent dye-containing PEG compound and the following formula (III):

(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 is a divalent C _{1 to} C ₁₂ carbon atom which may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Hydrogen group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), Y is a biologically active substance And a cyclic acetylene compound represented by the formula (Ib), wherein the cyclic acetylene compound represented by formula (Ib) is bound to a physiological condition (in an aqueous solution, at room temperature and in the absence of a copper catalyst). It is characterized by synthesizing a PEGylated bioactive substance represented by:

  The deoxyfluoroPEG compound of the present invention has the following formula (II-a ′):

(In the formula, R ^a1 is a divalent C _{1 to} C ₆ hydrocarbon group, and n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) In this deoxyfluoroPEG compound, F in the formula (II-a ′) is, for example, ¹⁸ F.

  The fluorescent dye-containing PEG compound of the present invention has the following formula (II-b):

(In the formula, Z represents a monovalent group containing a fluorescent dye, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) The

  The sulfonylated PEG compound of the present invention has the following formula (II-c):

(In the formula, R ^h1 is substituted with a monovalent C _{1 to} C ₁₂ hydrocarbon group which may be substituted with a halogen atom, or a C _{1 to} C ₄ organic group which may contain a hetero atom or a halogen atom. An optionally substituted phenyl group, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, and n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.

  The method for producing a sulfonylated PEG compound of the present invention is a method for producing a sulfonylated PEG compound represented by the above formula (II-c), which is represented by the following formula (II-c-1):

(Wherein R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), a diazo transfer reagent sulfonyl azide compound, Is reacted in a solvent to give the following formula (II-c-2):

(Wherein R ^a1 and n have the same ^{meanings as} described above), and then the obtained compound represented by the formula (II-c-2) is reacted with a sulfonylating reagent in a solvent. A sulfonylated PEG compound represented by the formula (II-c) is synthesized.

  The method for producing a deoxyfluoroPEG compound of the present invention is a method for producing a deoxyfluoroPEG compound represented by the above formula (II-a ′), which is represented by the following formula (II-c):

(In the formula, R ^h1 is substituted with a monovalent C _{1 to} C ₁₂ hydrocarbon group which may be substituted with a halogen atom, or a C _{1 to} C ₄ organic group which may contain a hetero atom or a halogen atom. An optionally substituted phenyl group, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight, and ^A deoxyfluoroPEG compound represented by the above formula (II-a ′) labeled with [ ¹⁸ F] is synthesized by reacting with an ¹⁸ F] labeled fluorinating reagent in a solvent.

  The method for producing a fluorescent dye-containing PEG compound of the present invention is a method for producing a fluorescent dye-containing PEG compound represented by the formula (II-b), wherein the following formula (II-b-1):

(Wherein R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight) and this formula (II-b- A fluorescent dye-containing PEG compound represented by the formula (II-b) is synthesized by reacting a fluorescent dye having a functional group that reacts with the amino group of the compound represented by 1).

  The cyclic acetylene compound of the present invention has the following formula (III):

(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 is a divalent C _{1 to} C ₁₂ carbon atom which may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Hydrogen group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), Y is a biologically active substance Represents a monovalent group including).

  The cyclic acetylene compound of the present invention has the following formula (III-1):

(Wherein R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom, R ^c1 and R ^c2 each independently represent a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or -R ^d1 (OCH ₂ CH ₂ ) _m R ^d2- (R ^d1 may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m . C ₁ -C ₁₂ hydrocarbon group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, and m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) ).

  The method for producing a cyclic acetylene compound of the present invention is a method for producing a cyclic acetylene compound represented by the above formula (III-1), which is represented by the following formula (III-1-1):

(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^e1 represents a divalent C _{1 to} C ₅ hydrocarbon group), and a cyclic acetylene compound represented by the following formula (III- 1-2):

(In the formula, R ^c1 and R ^c2 are each independently a hydrogen atom or a fluorine atom, R ^c3 is a C _{1 to} C ₈ hydrocarbon group or —R ^d3 (OCH ₂ CH ₂ ) _m R ^d4 — (R ^d3 is divalent) C _{1 to} C ₈ hydrocarbon group or OCH ₂ CH ₂ , R ^d4 may have an amide group, m is a divalent C _{1 to} C ₆ hydrocarbon group, m is in the range of 1 kDa to 40 kDa in terms of molecular weight OR ^c4 represents a leaving group that is eliminated by the reaction with the amino group of the fluorescent dye-containing PEG compound represented by (III-1) above.) The fluorescent dye-containing PEG compound represented by the formula (III-1) is synthesized.

  The method for producing a cyclic acetylene compound of the present invention is a method for producing a cyclic acetylene compound represented by the above formula (III), which is represented by the following formula (III-1):

(Wherein R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom, R ^c1 and R ^c2 each independently represent a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or -R ^d1 (OCH ₂ CH ₂ ) _m R ^d2- (R ^d1 may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m . C ₁ -C ₁₂ hydrocarbon group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, and m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) And a biologically active substance having a functional group that reacts with the maleimide group of the cyclic acetylene compound represented by the formula (III-1) to react with the above-described formula (III). A cyclic acetylene compound represented by the formula is synthesized.

According to the present invention, there is provided a method for non-invasively and quantitatively analyzing the pharmacokinetics of the PEGylated bioactive substance labeled with [ ¹⁸ F] F in real time by positron tomography (PET).

  According to the present invention, there is provided a method for non-invasively and quantitatively analyzing the pharmacokinetics of the fluorescently labeled PEGylated bioactive substance in real time by a fluorescence detection method.

[ ¹⁸ F] F labeling of long-chain PEG having a molecular weight of several thousand or more has no examples other than the report of the present inventors (Non-patent Document 2). Since proteins are easily denatured by heat, chemicals, etc., [ ¹⁸ F] F labeling of proteins with a long chain PEG having a molecular weight of several thousand or more is more difficult, and there is no precedent. Therefore, the novelty of the present invention is clear.

The development of PEGylated proteins and PEGylated antibodies as drug candidates has been actively studied worldwide, but there are no examples of analyzing their pharmacokinetics in vivo. Since the synthesis conditions of the long-chain PEG to which the protein is bound and [ ¹⁸ F] F-labeled long-chain PEG are completely different, according to the present invention, each unit is synthesized separately in advance and then subjected to physiological conditions. By combining the two in the Huisgen reaction, it becomes possible for the first time to label [ ¹⁸ F] F of a protein with a long-chain PEG with a molecular weight of several thousand or more. According to the present invention, the pharmacokinetics of various [ ¹⁸ F] F-PEGylated compounds can be visualized / quantified in real time by PET.

  If the PEGylated bioactive substance of formula (Ia) or formula (Ib) is synthesized using PEG (molecular weight 2 kDa to 40 kDa) as linker X, PEG derived from formula (II-a) or formula (II-b) The Huisgen reaction ligation moiety fits in the middle of the combined long PEG chain with a molecular weight of 4 kDa to 80 kDa. For this reason, the influence which a connection part has on the whole molecule | numerator can be reduced. As a result, it is considered that a result almost the same as the pharmacokinetics of the actual PEGylated bioactive substance can be obtained.

  The use of the compound of formula (I-b) combined with a fluorescent dye has an advantage that it can be visualized and quantified more easily than PET.

In our method, the reaction from formula (II-c) to formula (II-a) is completed within 20 minutes. If the connection between formula (II-a) and formula (III) can be completed within about 20 minutes, a sufficient amount of radioactivity of formula (Ia) can be secured even with [ ¹⁸ F] F having a half-life of 110 minutes. In addition, it is described in Feringa, B. et al., Angew. Chem. 2011 and the like that the linker part is much smaller than the PEG part, and thus has little influence on the whole molecule.

  Since PET is extremely sensitive, it is possible to safely obtain kinetic information in humans using a very small amount of a PEGylated drug candidate compound. The present invention can provide a very powerful technique for promoting microdose clinical trials. This provides a revolutionary method for drug discovery research, and its ripple effect is very large. The present invention can be a basic tool used by pharmaceutical companies and drug discovery researchers around the world.

When biomarkers specific to diseases (antibodies, peptides, nucleic acids, low molecular weight compounds, etc.) are bound to long-chain [ ¹⁸ F] F-PEG to form PET probes, they can be used for diagnosis of various diseases. As cancer diagnosis by PET using [ ¹⁸ F] F-FDG (fluorodeoxyglucose) is widespread, infrastructure development of PET effective for noninvasive whole body scanning and visualization is progressing. Enhancement of diagnostic agents using [ ¹⁸ F] F-PEG will be a pillar supporting early medical care in the near future.

Since PEGylated proteins and PEGylated antibodies are also widely used as reagents for biochemical research, the use of [ ¹⁸ F] F-PEG and PEG combined with fluorescent dyes can be further expanded.

6 is a chart showing the results of HPLC analysis of the reaction mixture of Compound 64 and Alexa Fluor 750 Carboxylic Acid Succinimidyl Ester in Example 3. 6 is a chart showing the results of analyzing the reaction mixture (crude product) of Compound 64 and Alexa Fluor 647 Carboxylic Acid Succinimidyl Ester in Example 4 by HPLC. 6 is a chart showing the results of analyzing the reaction mixture (crude product) of Compound 64 and Alexa Fluor 647 Carboxylic Acid Succinimidyl Ester in Example 4 by HPLC. 6 is a chart showing the results of HPLC analysis of the reaction mixture of Compound 83 and Compound 56 in Example 9. 6 is a chart showing the results of HPLC analysis of the reaction mixture of Compound 83 and Compound 56a in Example 11. 6 is a chart showing the results of HPLC analysis of the reaction mixture of Compound 83 and Compound 56a in Example 11. 6 is a chart showing the results of HPLC analysis of the reaction mixture of compound 84 and compound 56 in Example 12. 4 is a chart showing the results of analyzing Compound 84 in Example 13 by HPLC. 4 is a chart showing the results of HPLC analysis of the reaction mixture of compound 84 and compound 56a in Example 13. 4 is a chart showing the results of HPLC analysis of the reaction mixture of compound 84 and compound 56a in Example 13. In Example 14, the results of in vivo imaging of the pharmacokinetics of Alexa647 fluorescence after administration of the control compound (86a) to the tail vein of A549 human lung cancer cell transplanted mice are shown. In Example 14, RGDfC-PEG (85a) is administered to the A549 human lung cancer cell-transplanted mouse into the tail vein, and the pharmacokinetics thereof are shown in vivo imaging using Alexa647 fluorescence. In Example 14, the mouse was dissected 3 hours after administration, and the results of ex vivo imaging with IVIS of the distribution of the control compound (86a) and RGDfC-PEG (85a) in blood, each organ, and tumor are shown. 6 is a chart showing the results of HPLC analysis of the reaction mixture of Compound 83 and Compound 52 in Example 15. 6 is a chart showing the results of HPLC analysis of the reaction mixture of compound 81 and compound 52 in Example 16. 6 is a chart showing the results of HPLC analysis of the reaction mixture of compound 81 and compound 52 in Example 16.

The present invention is described in detail below.
(DeoxyfluoroPEG compound)
The deoxyfluoroPEG compound of the present invention is represented by the formula (II-a ′). This deoxyfluoroPEG compound can be synthesized as follows.

First, the compound HO (CH ₂ CH ₂ O) _n —R ^a1 —NH ₂ represented by the above formula (II-c-1) is used as a starting material, and reacted with a sulfonyl azide compound of a diazo transfer reagent. A compound HO (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ represented by the formula (II-c-2) is synthesized.

The starting material HO (CH ₂ CH ₂ O) _n -R ^a1 -NH ₂ is one in which n is in the range of 1 kDa to 40 kDa in terms of molecular weight. A commercially available product can be used.

  n is in the range of 1 kDa to 40 kDa in terms of molecular weight, preferably in the range of 2 kDa to 40 kDa, more preferably in the range of 2 kDa to 30 kDa.

R ^a1 represents a divalent C ₁ -C ₆ hydrocarbon group. A divalent C ₁ -C ₆ alkylene group is preferred, and a divalent C ₂ -C ₄ alkylene group is more preferred.

The sulfonyl azide compound R—SO ₂ N ₃ is known as a diazo transfer reagent. Among them, imidazole-1-sulfonyl azide hydrochloride is preferable because of its good storage stability, crystallinity, and high safety.

  The conversion of primary amines to azides using imidazole-1-sulfonyl azide hydrochloride is described in Ethan D. Goddard-Borger, Robert V. Stick, Org. Lett. 2007, 9, 3797-3800. Yes.

For example, it dissolved _{HO (CH 2 CH 2 O)} n -R a1 -NH 2 with 1 equivalent of K ₂ CO ₃ 2 equivalents, and CuSO ₄ · H ₂ O catalytic amount in methanol, imidazole -1 at room temperature -1.5 eq. Of sulfonyl azide hydrochloride was added and reacted by stirring for 24 hours, acidified with concentrated hydrochloric acid, etc., extracted with an organic solvent, the organic layer was dried over anhydrous MgSO ₄ , and the solvent was distilled off under reduced pressure. The object can be obtained.

Next, HO (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ obtained by this reaction is reacted with a sulfonylating reagent in a solvent to obtain a compound R ^h1 SO represented by the above formula (II-c). ₂ O (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ is synthesized.

Here, R ^h1 is a monovalent C _{1 to} C ₁₂ hydrocarbon group which may be substituted with a halogen atom such as a fluorine atom, or a C _{1 to} C ₄ organic group which may contain a hetero atom or a halogen atom. (For example, a methyl group etc.) The phenyl group which may be substituted is shown.

This reaction is preferably carried out in the presence of an organic base. As the organic base, for example, Et ₃ N, RNMe ₂ or the like can be used. Here, examples of R of RNMe ₂ include an alkyl group having 1 to 6 carbon atoms and an arylalkyl group having 7 to 12 carbon atoms. Of these, a methyl group is preferable. Further, the RNMe ₂ catalyst may be used in the form of an appropriate salt such as an HCl salt, for example, and in the case of Me ₃ N, it is preferably used as an HCl salt.

Examples of the sulfonylating reagent include p-toluenesulfonyl chloride (TsCl), methanesulfonyl chloride (MsCl), trifluoromethanesulfonic anhydride (Tf ₂ O), nonafluorobutanesulfonic acid fluoride (NfF), and the like. it can.

  Examples of the solvent used for the sulfonylation reaction include dichloromethane, 1,2-dichloroethane, trifluorotoluene, acetonitrile, toluene and the like.

This sulfonylation reaction is, for example, 1 to 10 equivalents of a sulfonylating reagent, 1 to 10 equivalents of Et ₃ N, 0.05 to RNMe ₂ relative to the raw material HO (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ . It can be carried out using a range of ˜1 equivalent.

  This sulfonylation reaction can be performed, for example, at a reaction temperature of −20 to 60 ° C. and a reaction time of 1 to 24 hours.

Purification after the reaction is difficult due to the high polarity of the target PEG compound due to its separation operation and normal phase column chromatography, and unreacted sulfonylating reagent and Et ₃ N sulfonic acid produced as a by-product Is difficult to remove. On the other hand, when the strong acid ion exchange resin Amberlite IR-120 and the strong basic ion exchange resin Amberlite IRA-400 are used (reference: Shuji Akai, Sho Ishida, Kentaro Hatanaka, Takayuki Ishii, Norihiro Harada, Hideo Tsukada, Naoto Oku, Molecular Pharmaceutics, 2011, 8, 302-308.) These impurities can be effectively removed.

Next, the obtained R ^h1 SO ₂ O (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ is reacted in a solvent with a fluorinating reagent to represent deoxy represented by the above formula (II-a ′). FluoroPEG compound F (CH ₂ CH ₂ O) _n —R ^a1 —N ₃ is synthesized.

Examples of the fluorinating reagent include tetra-n-butylammonium fluoride (nBu ₄ NF: TBAF), KF-Kryptofix- [2.2.2], CsF, and the like.

Here, when an [ ¹⁸ F] -labeled fluorinating reagent is used as the fluorinating reagent, the compound represented by the formula (II-a ′) can be labeled with ¹⁸ F. Changing ¹⁹ F to ¹⁸ F has little effect on reactivity. However, the reaction using [ ¹⁸ F] -labeled fluorinating reagent is performed by an automatic synthesizer to avoid the influence of radiation (Non-patent Document 2).

^{Since 18} F has a short half-life of 110 minutes, the [ ¹⁸ F] F labeling reaction must proceed in a short time. Therefore, selection of [ ¹⁸ F] -labeled fluorinating reagent and solvent is important.

Examples of the solvent include acetonitrile (MeCN), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and the like. T-Butanol (t-BuOH) is known as a solvent that improves reactivity and selectivity in fluorination using CsF and nBu ₄ NF (Kim, DW; Jeong, HJ; Lim, ST; Sohn, MH; Katzenellenbogen, JA; Chi, DY Facile Nucleophilic Fluorination Reactions Using tert-Alcohols as a Reaction Medium: Significantly Enhanced Reactivity of Alkali Metal Fluorides and Improved Selectivity. J. Org. Chem. 2008, 73, 957-962.).

Examples of the combination of [ ¹⁸ F] -labeled fluorinating reagent and solvent include [ ¹⁸ F] nBu ₄ NF / DMF, [ ¹⁸ F] KF-Kryptofix- [2.2.2] / MeCN, [ ¹⁸ F] nBu ₄ NF ^{/ MeCN, [18 F] KF} -Kryptofix- [2.2.2] / t-BuOH, [18 F] nBu 4 NF / t-BuOH, but like ^{[18 F] CsF / t-} BuOH, [18 Considering that F] F has a short half-life of 110 minutes, taking into account rapid labeling to ensure a sufficient amount of radioactivity, for example, completion of the reaction in 20 minutes, [ ¹⁸ F] nBu ₄ NF / DMF is effective.

This labeling reaction is performed using, for example, an [ ¹⁸ F] -labeled fluorinating reagent for R ^h1 SO ₂ O (CH ₂ CH ₂ O) _n —XN ₃ under an inert gas atmosphere such as argon. Can be performed at 150 ° C.

Purification after the reaction can be carried out using the strongly acidic ion exchange resin Amberlite IR-120 and the strongly basic ion exchange resin Amberlite IRA-400.
(Fluorescent dye-containing PEG compound)
The fluorescent dye-containing PEG compound represented by the formula (II-b) includes a compound represented by the formula (II-b-1) and an amino group of the compound represented by the formula (II-b-1). It can synthesize | combine by making it react with the fluorescent dye which has a functional group which reacts.

  In the formula (II-b), Z is a monovalent group containing a fluorescent dye. The fluorescent dye is not particularly limited. For example, a fluorescent dye of the fluorescein family (manufactured by Integrated DNA Technologies), a fluorescent dye of the polyhalofluorescein family (manufactured by Applied Biosystems Japan Co., Ltd.), a hexachlorofluorescein family Fluorescent dyes (Applied Biosystems Japan), Coumarin family fluorescent dyes (Invitrogen), Rhodamine family fluorescent dyes (GE Healthcare Biosciences), cyanine family fluorescence Dyes, indocarbocyanine family fluorescent dyes, oxazine family fluorescent dyes, thiazine family fluorescent dyes, squaraine family fluorescent dyes, chelated lanthanide family fluorescent dyes, BODIPY® Lee's fluorescent dye (manufactured by Invitrogen), naphthalenesulfonic acid family fluorescent dye, pyrene family fluorescent dye, triphenylmethane family fluorescent dye, Alexa Fluor (registered trademark) dye series (Invitrogen Corporation) Manufactured). The absorption wavelength (nm) and emission wavelength of typical fluorescent dyes included in these families are, for example, in the range of 450 to 850 nm.

R ^a1 represents a divalent C ₁ -C ₆ hydrocarbon group. A divalent C ₁ -C ₆ alkylene group is preferred, and a divalent C ₂ -C ₄ alkylene group is more preferred.

  n is in the range of 1 kDa to 40 kDa in terms of molecular weight, preferably in the range of 2 kDa to 40 kDa, more preferably in the range of 2 kDa to 30 kDa.

As the fluorescent dye having a functional group that reacts with the amino group of the compound represented by the formula (II-b-1), for example, —COOR ^f1 (OR ^f1 is an excellent elimination as a functional group that reacts with the amino group) A fluorescent dye having a functional group, for example, N-hydroxysuccinimide as HOR ^f1 ).

The fluorescent dye-containing PEG compound represented by the formula (II-b) includes, for example, a compound represented by the formula (II-b-1) and a compound represented by the formula (II-b-1). It can be synthesized by reacting a fluorescent dye having a functional group that reacts with an amino group in a solvent such as DMF / NaHCO ₃ aq at around room temperature.
(Cyclic acetylene compound)
The cyclic acetylene compound represented by the formula (III) is synthesized by reacting the cyclic acetylene compound represented by the formula (III-1-1) with the maleimide compound represented by the formula (III-1-2). can do.

In the cyclic acetylene compound represented by the formula (III), R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom, and R ^c1 represents a hydrogen atom or a fluorine atom.

X may be composed of a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 is an amide group or (OCH ₂ CH ₂ ) _m oxygen atom. A divalent C _{1 to} C ₁₂ hydrocarbon group which may have a carbamate group (wherein C _{1 to} C ₁₂ do not include the carbon atom of an amide group or a carbamate group), R ^d2 Is a divalent C _{1 to} C ₆ hydrocarbon group optionally having an amide group (where C _{1 to} C ₆ do not include the carbon atom of the amide group), m is 1 kDa to 40 kDa in terms of molecular weight Represents an integer within the range of

The divalent C ₁ -C ₁₂ hydrocarbon group of X is preferably a divalent C ₁ -C ₁₂ alkylene group, more preferably a divalent C ₁ -C ₆ alkylene group.

When R ^{d1 of} X is a divalent C _{1 to} C ₁₂ hydrocarbon group not containing an amide group or a carbamic acid ester group, it is preferably a divalent C _{1 to} C ₁₂ alkylene group, more preferably a divalent C _1. ~C ₆ is an alkylene group. When R ^{d1 of} X is a divalent C _{1 to} C ₁₂ hydrocarbon group having an amide group or a carbamate group that may be configured with an oxygen atom of (OCH ₂ CH ₂ ) _m , for example, -R ^g1 NHCOR ^g2 - (R ^g1, R ^g2 represent each independently a C ₁ -C ₅ alkylene ^{group.), - R g1 NHCOOR g2} - (R g1, R g2 represents a C ₁ -C ₅ alkylene group independently. ^{), - R g1 NHCOO- (R} g1 represents a C ₁ -C ₅ alkylene group, NHCOO- is (OCH ₂ CH ₂₎ include constructed) such as with an oxygen atom of _m.. R ^d2 is a divalent C _{1 to} C ₆ hydrocarbon group which may have an amide group, preferably a C _{1 to} C ₄ alkyl group or —R ^g3 NHCOR ^g4 — (R ^g3 and R ^g4 are each independently represent an C ₁ -C ₅ alkylene group.) it is. m is in the range of 1 kDa to 40 kDa in terms of molecular weight, preferably in the range of 2 kDa to 40 kDa, more preferably in the range of 2 kDa to 30 kDa.

  Y represents a monovalent group containing a biologically active substance. Biologically active substances are substances and compounds that exhibit physiological or pharmacological effects on living organisms. Even if they can be obtained from the natural world by appropriate methods, they are produced by genetic engineering techniques or other artificial techniques. It may be the same substance as that of nature, and may be a modified form thereof. Specifically, for example, peptides, nucleic acid related substances, low molecular compounds, antigens, antibodies, receptors, adhesion molecules, cytokines, hormones, polysaccharides, oligosaccharides, oligopeptides, enzymes, antibiotics, enzyme inhibitors, receptors An agonist, a receptor antagonist, etc. are mentioned.

The cyclic acetylene compound represented by the formula (III) includes a functional group that reacts with the cyclic acetylene compound represented by the formula (III-1) and the maleimide group of the cyclic acetylene compound represented by the formula (III-1). It can be synthesized by reacting with a bioactive substance having a reaction in a solvent such as DMF / NaHCO ₃ aq at around room temperature.

  Examples of the functional group that reacts with the maleimide group of the cyclic acetylene compound represented by the formula (III-1) in this biologically active substance include a thiol group.

The cyclic acetylene compound represented by the formula (III-1) includes a cyclic acetylene compound represented by the formula (III-1-1) and a maleimide compound represented by the formula (III-1-2). It can be synthesized by adding a base such as NaHCO ₃ or Et ₃ N and reacting in a solvent such as THF or aq.

In the formula (III-1-1), R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom. R ^e1 is a divalent C ₁ -C ₅ hydrocarbon group, preferably a C ₁ -C ₅ alkylene group.

In formula (III-1-2), R ^c1 and R ^c2 each independently represent a hydrogen atom or a fluorine atom. R ^c3 is a C _{1 to} C ₈ hydrocarbon group or —R ^d3 (OCH ₂ CH ₂ ) _m R ^d4 — (R ^d3 is a divalent C _{1 to} C ₈ hydrocarbon group or OCH ₂ CH ₂ , R ^d4 is an amide A divalent C _{1 to} C ₆ hydrocarbon group which may have a group (where C _{1 to} C ₆ do not include the carbon atom of the amide group), m is in the range of 1 kDa to 40 kDa in terms of molecular weight OR ^c4 represents the same group as the leaving group OR ^{f1 that} is eliminated by the reaction with the amino group of the fluorescent dye-containing PEG compound represented by (II-b-1).

The C _{1 to} C ₈ hydrocarbon group of R ^c3 is preferably a divalent C _{1 to} C ₈ alkylene group, more preferably a divalent C _{1 to} C ₆ alkylene group.

In —R ^d3 (OCH ₂ CH ₂ ) _m R ^d4 — of R ^c3 , R ^d3 is a divalent C _{1 to} C ₈ alkylene group, more preferably a divalent C _{1 to} C ₆ alkylene group. R ^d4 is a divalent C ₁ -C ₆ hydrocarbon group, preferably a C ₁ -C ₄ alkyl group. m is in the range of 1 kDa to 40 kDa in terms of molecular weight, preferably in the range of 2 kDa to 40 kDa, more preferably in the range of 2 kDa to 30 kDa.
(PEGylated bioactive substance labeled with [ ¹⁸ F] F)
The [ ¹⁸ F] F labeled PEGylated bioactive substance represented by the formula (Ia) includes the [ ¹⁸ F] fluoro PEG compound represented by the formula (II-a) and the formula (III). The cyclic acetylene compound represented can be synthesized by reacting under physiological conditions (in an aqueous solution, at room temperature, and in the absence of a copper catalyst).

PEGylated bioactive substances labeled with [ ¹⁸ F] F of the present invention include those using PEG (molecular weight of 2 kDa to 40 kDa) as linker X of formula (Ia). It will be understood that the ability to synthesize such compounds is clear from the results of the examples described later and from common technical knowledge already known to those skilled in the art. And, as described above, the synthesis of a long-chain PEG compound having such a PEG derived from the formula (II-a) and a PEG derived from the linker X is carried out by combining a long-chain PEG having a protein previously bound thereto and [ ¹⁸ F] F Since the synthesis conditions of labeled long-chain PEG are completely different, long-chain PEGs with molecular weights of several thousand or more are bound for the first time by synthesizing each unit separately and then coupling them together using a Huisgen reaction under physiological conditions. This is based on the idea that [ ¹⁸ F] F labeling of the obtained protein may be possible, and was supported to the extent that it can be carried out in the examples described later. According to such a long-chain PEG compound, since the Huisgen reaction linking portion fits in the middle of the long-chain PEG chain having a molecular weight of 4 kDa to 80 kDa combined with the PEG derived from the formula (II-a), the linking portion is the whole molecule. Can be reduced.

By using this [ ¹⁸ F] F-labeled PEGylated bioactive substance, its pharmacokinetics can be analyzed non-invasively and quantitatively in real time by positron tomography (PET).

  This Huisgen cycloaddition reaction of azide and alkyne greatly changes the structural characteristics of biomolecules because azide and alkyne have high chemical stability and are almost nonpolar and difficult to form hydrogen bonds. There is a feature that there is nothing. However, with no catalyst, the reaction rate was very slow and usually heating for a long time was required. In 2002, a method using a copper catalyst was reported by Meldal and Sharpless et al., And the reaction under rapid and mild conditions became possible when the copper catalyst activated the alkyne.

However, in the present invention, by using the cyclic acetylene compound represented by the highly reactive formula (III), the reaction proceeds at the same rate as the method using the copper catalyst without using the copper catalyst. Since copper ion has cytotoxicity, it is a great advantage that it is not necessary, and it is also suitable for applications such as the above-described pharmacokinetic analysis using PET and the following pharmacokinetic analysis using fluorescent dyes.
(Fluorescently labeled PEGylated bioactive substance)
The fluorescently labeled PEGylated bioactive substance represented by the formula (Ib) comprises a fluorescent dye-containing PEG compound represented by the formula (II-b) and a cyclic acetylene compound represented by the formula (III). It can be synthesized by reacting under physiological conditions (in an aqueous solution, at room temperature, and in the absence of a copper catalyst).

  By using this fluorescently labeled PEGylated bioactive substance, its in vivo kinetics can be analyzed noninvasively and quantitatively in real time by various fluorescent detection methods.

EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
<Examples 1-3> Synthesis of a functionalized novel PEG having an azide group Using a commercially available PEG having an amino group at the terminal (2 kDa, 58) as a starting material, using the method of Goddard-Borger et al. The terminal amino group was azidated to give 59. Subsequently, the terminal hydroxyl group was tosylated to obtain 60. By applying the PEG purification method using the cation and anion exchange resin developed by the present inventors, it was possible to efficiently isolate even the highly polar PEG derivative 60. Finally, by fluorination using nBu ₄ NF, the desired PEG 52 was obtained in a yield of 79% over 3 steps. For the purification, an ion exchange resin was similarly used.

<Example 1>
Synthesis of Compound 59

HO (CH ₂ CH ₂ O) _n C ₃ H ₆ NH ₂ (58, average molecular weight: 2 kDa, 0.40 g, 0.20 mmol), K ₂ CO ₃ (55 mg 0.40 mmol), CuSO ₄・ H ₂ O (2.5 mg, 10 μmol) was dissolved in MeOH (2.0 ml), and Imidazole-1-sulfonyl azide · HCl (63 mg, 0.30 mmol) was added at room temperature, followed by stirring for 24 hours. The solvent was evaporated under reduced pressure, 1N HCl (5 ml) was added to the residue, and the mixture was extracted 3 times with CH ₂ Cl ₂ (5 ml). The organic layer was dried over anhydrous MgSO ₄ and the solvent was distilled off under reduced pressure to obtain 59 (0.38 g, 97%).
¹ H NMR (500 MHz, CDCl ₃ ): 1.85 (2 H, quint, J = 6.5 Hz), 3.39 (2 H, t, J = 6.5 Hz), 3.48-3.79 (ca.200 H, m). ¹³ C NMR (500 MHz, CDCl ₃ ): 29.0, 48.4, 61.4, 67.8, 70.1, 70.3, 70.4, 70.5, 72.8. IR (CHCl ₃ ): 2099 cm ^-1 .
MS (MALDI-TOF): m / z calcd for C ₈₉ H ₁₇₉ N ₃ O ₄₄ K [M (n = 43) + K] ⁺ : 2033.1499, found: 2033.2044.
Synthesis of compound 60

59 (0.19 g, 95 μmol), TsCl (0.11 g, 0.57 mmol), Me ₃ N ・ HCl (1.0 mg, 10 μmol) dissolved in CH ₂ Cl ₂ (2.0 ml), and Et ₃ N (0.10 ml) at room temperature , 0.67 mmol) and stirred for 3 hours. The solvent was distilled off under reduced pressure and dissolved in H ₂ O-MeCN (1: 1, 20 ml). Activated strongly acidic ion exchange resin Amberlite IR-120 (3.0 g) and activated strongly basic ion exchange resin Amberlite IRA-400 (3.0 g) were added, and the mixture was vigorously stirred for about 20 minutes and filtered. The filtrate was concentrated under reduced pressure to give 60 (0.19 g 92%).
¹ H NMR (500 MHz, CDCl ₃ ): 1.84 (2 H, quint, J = 6.5 Hz), 2.44 (3 H, s), 3.38 (2 H, t, J = 6.5 Hz), 3.48-3.78 (ca .200 H, m), 4.14 ( 2 H, t, J = 5.0 Hz), 7.33 (2 H, d, J = 8.0 Hz), 7.78 (2 H, d, J = 8.0 Hz). 13 C NMR ( 500 MHz, CDCl ₃ ): 21.6, 29.1, 48.4, 67.8, 68.6, 69.2, 70.3, 70.5, 70.7, 127.9, 129.8, 132.9, 144.7. IR (CHCl ₃ ): 2099 cm ^-1 .
MS (MALDI-TOF): m / z calcd for C ₉₄ H ₁₈₁ N ₃ O ₄₅ SK [M (n = 42) + K] ⁺ : 2143.1325, found: 2143.3302.
<Example 2>
Synthesis of compound 52

Under an argon atmosphere, 60 (40 mg, 20 μmol) was dissolved in anhydrous DMF (0.5 ml), nBuN ₄ F (1.0 M THF solution, 30 μl, 0.30 μmol) was added, and the mixture was stirred at 80 ° C. for 20 minutes. After dissolving in H ₂ O-MeCN (1: 1, 20 ml), activated strong acidic ion exchange resin Amberlite IR-120 (2.0 g) and activated strong basic ion exchange resin Amberlite IRA-400 (2.0 g) was added and stirred vigorously for about 20 minutes and filtered. The filtrate was concentrated under reduced pressure to give 52 (35 mg 88%).
¹ H NMR (500 MHz, CDCl ₃ ): 1.84 (2 H, quint, J = 6.5 Hz), 3.38 (2 H, d, J = 6.5 Hz), 3.47-3.78 (ca.200 H, m), 4.55 . (2 H, td, J = 4.5, 52.0 Hz) 13 C NMR (500 MHz, CDCl 3):. 29.1, 48.4, 67.8, 70.3, 70.5, 70.7, 83.1 (d, J = 168 Hz) 19 F NMR (470 MHz, CDCl ₃ ): -223 (tt, J = 29, 47 Hz)
IR (CHCl ₃ ): 2099 cm ^-1
MS (MALDI-TOF): m / z calcd for C ₈₉ H ₁₇₈ N ₃ O ₄₃ FK [M (n = 43) + K] ⁺ : 2035.1455, found: 2035.2070.
<Example 3>
Synthesis of Compound 64 By protecting 58 commercially available amino groups and tosylating the hydroxyl group, 62 was obtained in a 2-step 89% yield. Subsequently, the target PEG 64 was quantitatively obtained by introducing azide nucleophilically and deprotecting the amino group. In the purification in each step, PEG, which is difficult to purify, was efficiently isolated by washing with an ion exchange resin or a low polarity solvent.

Synthesis of Compound 62

HO (CH ₂ CH ₂ O) _n (CH ₂ ) ₃ NH ₂ (58, average molecular weight: 2 kDa, 0.10 g, 50 μmol) was dissolved in CH ₂ Cl ₂ -1M NaOH water (1: 1, 1.0 ml), Boc ₂ O (23 μl, 0.10 mmol) was added at room temperature and stirred for 19 hours. The solvent was distilled off under reduced pressure, the residue was dissolved in CH ₂ Cl ₂ (1.0 ml), TsCl (57 mg, 0.30 mmol), Me ₃ N ・ HCl (1.0 mg, 10 μmol), Et ₃ N (49 μl, 0.35 mmol) was added and stirred at room temperature for 24 hours. After removing the solvent under reduced pressure and dissolving in H ₂ O-MeCN (1: 1, 20 ml), activated strong acidic ion exchange resin Amberlite IR-120 (2.0 g) and activated strong basic ion exchange Resin Amberlite IRA-400 (2.0 g) was added and stirred vigorously for about 20 minutes and filtered. The filtrate was concentrated under reduced pressure to obtain 62 (0.10 g, 89%).
¹ H NMR (400 MHz, CDCl ₃ ): 1.40 (9 H, s), 1.72 (2 H, quint, J = 6 Hz), 2.42 (3 H, s), 3.18 (2 H, dd, J = 12 , 6 Hz), 3.47-3.78 (ca.200 H, m), 4.12 (2 H, t, J = 5 Hz), 7.32 (2 H, d, J = 8 Hz), 7.76 (2 H, d, J = 8 Hz).
HRMS (MALDI-TOF): m / z calcd for C ₁₀₁ H ₁₉₅ NO ₄₈ SK [M (n = 43) + K] ⁺ : 2261.2206, found: 2261.2132.
Synthesis of compound 63

62 (0.10 g, 44 μmol) was dissolved in DMF (0.5 ml), NaN ₃ (8.6 mg, 0.13 mmol) was added at room temperature, and the mixture was stirred at 100 ° C. for 2 hours. After removing the solvent under reduced pressure and dissolving in H ₂ O-MeCN (1: 1, 20 ml), activated strong acidic ion exchange resin Amberlite IR-120 (2.0 g) and activated strong basic ion exchange Resin Amberlite IRA-400 (2.0 g) was added and stirred vigorously for about 20 minutes and filtered. The filtrate was concentrated under reduced pressure to obtain 63 (0.10 g, quant.).
¹ H NMR (500 MHz, CDCl ₃ ): 1.41 (9 H, s), 1.73 (2 H, quint, J = 6 Hz), 3.19 (2 H, dd, J = 13, 6 Hz), 3.37 (2 H, t, J = 5 Hz) 3.47-3.78 (ca.200 H, m)
HRMS (MALDI-TOF): m / z calcd for C ₉₄ H ₁₈₈ N ₄ O ₄₅ K [M (n = 43) + K] ⁺ : 2132.2183, found: 2132.2180.
Synthesis of compound 64

63 (0.10 g, 44 · ol) was dissolved in 4N HCl / EtOAc (1.0 ml) and stirred at room temperature for 4 hours. The solvent was distilled off under reduced pressure, and the residue was washed with hexane to obtain 64 (94 mg, quant.).
¹ H NMR (500 MHz, D ₂ O / CDCl ₃ ): 2.00-2.10 (2 H, m), 3.19 (2 H, t, J = 5 Hz), 3.39 (2 H, t, J = 5 Hz) 3.47-3.78 (ca.200 H, m).
HRMS (MALDI-TOF): m / z calcd for C ₈₉ H ₁₈₀ N ₄ O ₄₃ K [M (n = 43) + K] ⁺ : 2032.1658, found: 2032.1563.
Subsequently, Alexa Fluor 750 having the maximum fluorescence emission at 64 and 775 nm was bound.

Synthesis of Compound 56

64 (0.30 mg, 1.5 μmol) and Alexa Fluor 750 Carboxylic Acid, Succinimidyl Ester (90 μg) were dissolved in DMF (50 μl) and NaHCO ₃ water (0.15 M, 50 μl), and the mixture was stirred at room temperature for 21 hours. Purification by reverse phase HPLC (MeCN-H ₂ O, 7: 3) gave 56 (65%). The reaction solution was analyzed by HPLC and detected at 700 nm (FIG. 1). There are usually no compounds that absorb in this region. Therefore, all the absorption peaks were considered to be derived from Alexa Fluor, suggesting that the intended reaction had progressed. The yield was calculated based on the peak area. Thereafter, when the amount of the reactant was very small, the reaction was traced by HPLC.
<Example 4>
56a was synthesized by binding Alexa Fluor 647 with the maximum fluorescence emission at 64 and 647 nm.

64 (0.17 μmol) was dissolved in NaHCO ₃ aq. (0.1 M, 100 μl), and a DMF solution (100 μl) of Alexa Fluor 647 Carboxylic Acid, Succinimidyl Ester (0.18 μmol) was added. Stir at room temperature for 220 minutes. The reaction crude product was HPLC (5C ₁₈ -AR-II, 4.6 × 250 mm, MeCN: H ₂ O = 5: 95 (0 min) → 5: 95 (5 min) → 50: 50 (15 min) → 50 : 50 (25 min) → 95: 5 (30 min) → 100: 0 (35 min), flow rate 1.0 mL min ^-1 , detection: UV 650 nm and corona charged particle detector) (Figure 2A, B). A crude product (HPLC 1) and a crude product containing a new peak (target compound 56a) appearing at a retention time of 21 min by comparison of the mixture of Alexa 647 Carboxylic Acid, Succinimidyl Ester and crude product (HPLC 2) Was used for the next reaction.
<Examples 5 and 6> Synthesis of highly reactive cyclooctyne Highly reactive cyclooctyne having a maleimide group at the end of the side chain was synthesized.
<Example 5>
A highly reactive cyclooctyne (72, 79) having a maleimide group at the end of the side chain was synthesized. First, dioxisuberenone was reacted with hydroxylamine hydrochloride to obtain oxime 68 quantitatively. Subsequently, Tokuyama et al. And Beckman rearrangement using excessive DIBAL and amide reduction (Cho, H .; Iwama, Y .; Sugimoto, K .; Mori, S .; Tokuyama, HJ Org. Chem. 2010, 75, 627 -636.) Was applied to 68 to give 8-membered amine 69 in 80% yield.

  73 was synthesized from β-alanine and compound 69 as raw materials.

  Next, maleimide unit 67 was synthesized according to the literature (Figueiredo, R.M .; Oczipka, P .; Frohlich, R .; Christmann, M. Synthesis 2008, 8, 1316-1318.).

  Next, the condensation reaction of maleimide unit 67 (X = OH) and compound 73 was examined. As a result, when the condensing agent EDC was used, 72 was produced, but the yield was 20% at the maximum (Entries 1-3) .However, when the reaction was carried out after converting 67 to acid chloride, a highly reactive cyclohexane was obtained. Octin72 was obtained in 40% yield (Entry 4).

  Another highly reactive cyclooctyne 79 was synthesized from 73 and 78.

Synthesis of compound 79
73 (212 mg, 0.623 mmol) and 78 (290 mg, 1.87 mmol) were dissolved in a mixture of THF (5.5 ml) and aqueous NaHCO ₃ (5.5 ml), and the mixture was stirred at room temperature for 30 minutes. NH ₄ Cl sat. Was added and extracted with CH ₂ Cl ₂ . The organic layer was dried over anhydrous MgSO ₄ and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography (hexane-EtOAc, 1: 1) to obtain 79 (139 mg, 62%).
¹ H NMR (300 MHz, CDCl ₃ ): 2.18-2.31 (1 H, m), 2.46-2.55 (1 H, m), 3.64 (1 H, d, J = 14 Hz), 3.54-3.63 (1 H , m), 3.68-3.80 (1 H, m), 5.14 (1 H, d, J = 14 Hz), 6.53 (1H, s), 7.22-7.41 (7 H, m), 7.69 (1 H, d , J = 7 Hz).
HRMS (MALDI-TOF): m / z calcd for C ₂₂ H ₁₆ N ₂ O ₃ Na [M + Na] ⁺ : 379.1053, found: 379.1052.
<Example 6>
Cyclooctin 81 into which PEG (Mw 2 kDa) was introduced was synthesized. That is, a commercially available PEG 80 having a carboxyl group and an amino group at the terminal was used as a starting material, and a maleimide group was introduced in the same manner as before. Subsequently, the carboxyl group was converted into an active ester with NHS and reacted with amine 73 to obtain 81 in 3 steps and 64% yield.

Synthesis of compound 81

80 (0.10 g, 46 μmol) and 78 (22 mg, 0.14 mmol) were dissolved in MeCN (0.5 ml) and aqueous NaHCO ₃ (0.5 ml), and the mixture was stirred at room temperature for 3 hours. 1M HCl water was added and extracted 3 times with CH ₂ Cl ₂ . The organic layer was dried over anhydrous MgSO ₄ and the solvent was distilled off under reduced pressure. The residue was dissolved in CH ₂ Cl ₂ (1.0 ml), NHS (16 mg, 0.14 mmol) and EDC (27 mg, 0.14 mmol) were added, and the mixture was stirred at room temperature for 16 hours. H ₂ O was added and extracted 3 times with CH ₂ Cl ₂ . The organic layer was dried over anhydrous MgSO ₄ and the solvent was distilled off under reduced pressure. The residue was dissolved in CH ₂ Cl ₂ (1.0 ml), 73 (25 mg, 92 μmol) and Et ₃ N (13 μl, 92 μmol) were added, and the mixture was stirred for 3 hours. 1M HCl water was added and extracted 3 times with CH ₂ Cl ₂ . The organic layer was dried over anhydrous MgSO ₄ and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography (CH ₂ Cl ₂ -MeOH, 10: 1). Thereafter, reverse phase HPLC: Purification by _{(MeCN-H 2 O, 7} 3), to give the 81 (72mg, 64%).
<Examples 7 to 11> Synthesis of molecules for visualizing pharmacokinetics of PEGylated peptides <Example 7>
Synthesis of Compound 82 First, the Huisgen reaction was examined using the azide PEG 52 and alkyne 79 synthesized above.

79 (4.9 mg, 14 μmol) was dissolved in MeCN (0.3 ml), 52 (20 mg, 10 μmol) was added at room temperature, and the mixture was stirred at room temperature for 15 minutes. The solvent was distilled off under reduced pressure, and the residue was purified by reverse phase HPLC (MeCN-H ₂ O, 95: 5) to obtain 82 (20 mg, 80%, mixture of two regioisomers 3: 2). It has not been determined which of the two regioisomers is the main product.

<Example 8>
Synthesis of compound 83
79 (0.2 mg, 0.56 μmol) and cyclo-RGDfC-SH (0.50 μmol) were dissolved in a mixture of DMF (70 μl) and NaHCO ₃ water (0.10 M, 70 μl) and stirred at room temperature for 24 hours. Analysis by HPLC (5C ₁₈ -AR-II, 4.6 × 250 mm, MeCN: H ₂ O = 1: 1, flow rate 1.0mLmin ^-1 , detection: UV 254 nm), 79 and cyclo-RGDfC-SH Different new peaks (retention time 3.3 minutes) were fractionated to give compound 83.
HRMS (MALDI-TOF): m / z calcd for C ₄₆ H ₅₁ N ₁₀ O ₁₀ S [M + H] ⁺ : 935.3505, found: 935.3492.

<Example 9>
As a control compound, 84 in which dodecanethiol was introduced instead of cyclo-RGDfC-SH was synthesized in the same manner.

79 (7.0 mg, 20 μmol) was dissolved in a mixture of MeCN (0.2 ml) and CH ₂ Cl ₂ (10 μl), and dodecanethiol (3.8 μl, 15.7 μmol), K ₂ CO ₃ (4.1 mg, 29 μmol) was added, and the mixture was stirred at room temperature for 11 hours. The solvent was distilled off under reduced pressure, and the residue was purified by column chromatography (hexane-EtOAc, 1: 1) to obtain 84 (6.8 mg, 78%).
¹ H NMR (300 MHz, CDCl ₃ ): 0.88 (3 H, t, J = 7 Hz), 1.21-1.37 (18 H, m), 1.44-1.70 (2 H, m), 2.19 (1 H, sext , J = 8 Hz), 2.36 (1 H, dt, J = 19, 3 Hz), 2.42-2.84 (3 H, m), 2.94 (1 H, ddd, J = 22, 19, 9 Hz), 3.46 -3.75 (3 H, m), 3.64 (1 H, d, J = 14 Hz), 5.14 (1 H, d, J = 14 Hz), 7.26-7.41 (7 H, m), 7.69 (1 H, d, J = 7 Hz).
HRMS (MALDI-TOF): m / z calcd for C ₃₄ H ₄₃ N ₂ O ₃ S [M + H] ⁺ : 559.2989, found: 559.2989.
<Example 10>
We tried to combine 83 and 56 by Huisgen reaction. As a result, 83 disappeared rapidly and compound 85 was obtained (FIG. 3).

Synthesis of Compound 85

83 (30 nmol) and 56 (45 nmol) were dissolved in DMF (50 μl) and H ₂ O (50 μl) and stirred at room temperature for 15 minutes.
<Example 11>
A Huisgen reaction of 83 and 56a was performed to obtain compound 85a.

83 (32 nmol) was dissolved in a 1: 1 mixture (8.0 μl) of DMF and NaHCO ₃ water, and a mixture of 56a (8 nmol) in DMF (12.5 μl) and MeCN (20 μl) was added. The reaction was stirred at room temperature for 8 hours. HPLC (5C ₁₈ -AR-II 4.6 × 250 mm, MeCN: H ₂ O = 5: 95 (0 min) → 5: 95 (5 min) → 50: 50 (15 min) → 50: 50 (25 min) → 95: 5 (30 min) → 100: 0 (35 min), flow rate 1.0 mL min ^-1 , detection: UV 254 nm, 650 nm and corona charged particle detector (see Fig. 4A, B)) The peak at 21 minutes was collected to obtain 85a.
<Example 12>
86 was synthesized by Huisgen reaction of 84 and 56 for background use. When detected at 700 nm, 56 disappeared, and a new peak with a retention time of 11.5 minutes is considered to be Alexa Fluor adduct 86 (FIG. 5). The yield was estimated to be 52% based on the peak area.

Synthesis of Compound 86

84 (60 nmol) and 56 (30 nmol) were dissolved in DMF (50 μl) and H ₂ O (50 μl), and the mixture was stirred at room temperature for 15 minutes. Analysis by reverse phase HPLC (MeCN-H ₂ O, 30: 70 → 100: 0) gave 86 (52%).
<Example 13>
As a control compound, 86a to which dodecanethiol was bonded instead of cyclo-RGDfC was synthesized in the same manner.

Synthesis of Compound 86a
84 (FIG. 6) A solution of (32 nmol) and 56a (8 nmol) in DMF (12.5 μl) was stirred at room temperature for 70 minutes. HPLC (5C ₁₈ -AR-II 4.6 × 250 mm, MeCN: H ₂ O = 5: 95 (0 min) → 5: 95 (5 min) → 50: 50 (15 min) → 50: 50 (25 min) → 95: 5 (30 min) → 100: 0 (35 min), flow rate 1.0 mL min ^-1 , detection: UV 254 nm, 650 nm and corona charged particle detector (see Fig. 7A, B)) The peak at 21 minutes was fractionated to obtain 86a.
<Example 14>
In vivo imaging of RGDfC-PEG (85a)
1. Experimental material samples: RGDfC-PEG (85a), control-PEG (86a)
Feed for mice rearing without chlorophyll: Oriental Yeast Co., Ltd.
Isoflurane (Escaine <registered trademark>): Merck Pharmaceutical Co., Ltd.
insuflon <registered trademark>: Unnomedical
2. Experimental method (culture of cancer cells)
A549 human lung cancer cell line was used as transplanted cancer cells. The culture medium is D-MEM / Ham's F-12 plus penicillin G (100 unit / mL) and streptomycin solution (100 μg / mL) plus inactivated fetal bovine serum (FBS). In addition, 10% FBS D-MEM / Ham's F-12 (P / S +) prepared was used. The cells were cultured in an incubator at 37 ° C. in the presence of 5% CO ₂ , and when confluent, the cells were detached with a 0.25% Trypsin / EDTA-PBS (−) solution and subcultured.
(Production of cancer-bearing mice)
As experimental animals, 5-week-old male BALB / c nu / nu mice (Japan SLC) were used. Mice were fed with chlorophyll-free food to reduce background during imaging.

A suspension of A549 cells (1.0 × 10 ⁷ cells / 0.2 mL / mouse) was transplanted into the left ventral region of the mouse and used for imaging when the tumor diameter reached about 10 mm.
(Sample preparation)
Each sample [RGDfC-PEG (85a), control-PEG (86a)] was dissolved at the time of use in an appropriate amount of physiological saline so as to be 10 nmol / mL.
(In vivo imaging)
After inserting a cannula (insuflon (registered trademark)) into the tail vein of the tumor bearing mouse, the mouse was anesthetized using isoflurane (escaine (registered trademark)) in a dedicated chamber. After fixing the mouse in the device of IVIS Lumina Imaging System (Xenogen), each prepared sample (2 nmol / 0.2 mL / mouse) was administered into the tail vein. Immediately after administration, Alexa647 fluorescence contained in each sample was imaged noninvasively. Three hours after the administration, the mice were dissected, and the distribution of 85a and 86a to blood, each organ, and tumor was imaged ex vivo with IVIS.
3. Experimental results
8A and 8B show the results of in vivo imaging of the pharmacokinetics of control-PEG (86a) or RGDfC-PEG (85a) administered to A549 human lung cancer cell-transplanted mice using Alexa647 fluorescence. In each sample, a transition from the kidney to the bladder was observed. The mouse was dissected 3 hours after administration, and the results of ex vivo imaging of 86a and 85a distribution to blood, organs, and tumors by IVIS are shown in FIG. From this result, significant accumulation of RGDfC-PEG (85a) in kidney and tumor was observed. Therefore, RGDfC-PEG (85a) was suggested to be useful for tumor imaging.
<Example 15>

83 (25 nmol) and 52 (Mw 2 kDa, 50 nmol) were dissolved in DMF (50 μl) and H ₂ O (50 μl), and the mixture was stirred at room temperature for 15 minutes. Analysis by reverse phase HPLC gave 87 (Figure 10).
<Example 16>

Synthesis of Compound 88
81 (0.26 μmol) was dissolved in MeCN (0.5 ml), 52 (0.19 μmol) was added, and the mixture was stirred at room temperature for 120 minutes. HPLC (5C ₁₈ -AR-II 4.6 × 250 mm, MeCN: H ₂ O = 1: 1, flow rate 0.4 mL min ⁻¹ , detection: UV 254 nm and corona charged particle detector, see FIGS. 11A and B) A peak with a retention time (14 minutes) was collected to obtain 88. In HPLC, 81 appears in 8 min, and 52 and 88 both appear in 14 min. Since 88 and 52 overlapped and the end point of the reaction could not be judged, the reaction was performed for 120 minutes just in case.
MS (MALDI-TOF): m / z calcd for C ₂₀₀ H ₃₇₁ N ₆ O ₈₈ FNa [M (n ₁ = n ₂ = 42) + Na] ⁺ : 4307.4622, found: 4307.3684.
<Example 17>

Synthesis of compound 90
After adding K ₂ CO ₃ (0.6 mg, 4.4 μmol) to 89 (2.2 μmol) MeCN (0.4 ml) solution, add 0.1 ml of dodecanethiol MeCN solution (24 mM) and stir the reaction at room temperature for 220 minutes. did. The crude product (Compound 90) was directly used in the next reaction.
HRMS (MALDI-TOF): m / z calcd for C ₁₁₁ H ₂₁₁ N ₃ O ₅₀ SK (M (n = 42) + K] ⁺ : 2457.3413, found: 2457.3437.
<Example 18>

Synthesis of compound 91
17.5 μl of 73 CH ₂ Cl ₂ solution (36 mM) was added to 90 (4.0 × 10 ² μmol) CH ₂ Cl ₂ (0.25 ml) solution and stirred at room temperature for 15 minutes to obtain Compound 91.
HRMS (MALDI-TOF): m / z calcd for C ₁₂₇ H ₂₂₆ N ₄ O ₄₉ SK [M (n = 43) + K] ⁺ : 2662.4668, found: 2662.4610.

Claims (17)

The following formula (Ia):
(In the formula, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 represents an amide group or a carbamic acid ester group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Divalent C _{1 to} C ₁₂ hydrocarbon group that may have, R ^d2 may be a divalent C _{1 to} C ₆ hydrocarbon group that may have an amide group, m is 1 kDa to 40 kDa in terms of molecular weight Y represents a monovalent group containing a biologically active substance, n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight, and R ^a1 represents _three nitrogen atoms of —N ₃ —. PEGylated bioactive substance labeled with [ ¹⁸ F] F, which is bound to any one of the nitrogen atoms at both ends. A process for producing the PEGylated bioactive substance according to claim 1, wherein the formula (II-a):
(Wherein, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon radical, n is an integer in the range of 1kDa~40kDa molecular weight basis.) And represented by ^[18 F] fluoro-PEG compound, the following formula (III):
(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2- (R ^d1 is a C _{1 to} C ₁₂ hydrocarbon group or divalent C _{1 to} C ₁₂ amide group or carbamic acid ester group-containing hydrocarbon group, R ^d2 is a divalent C _{1 to} C ₆ hydrocarbon group, m represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.), Y represents a monovalent group containing a biologically active substance.) And a cyclic acetylene compound represented by physiological conditions Labeled with [ ¹⁸ F] F, characterized in that the reaction is carried out under an aqueous solution (at room temperature and in the absence of a copper catalyst) to synthesize the PEGylated bioactive substance represented by the formula (Ia). A method for producing a PEGylated bioactive substance. Formula (Ib):
(In the formula, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 represents an amide group or a carbamic acid ester group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Divalent C _{1 to} C ₁₂ hydrocarbon group that may have, R ^d2 may be a divalent C _{1 to} C ₆ hydrocarbon group that may have an amide group, m is 1 kDa to 40 kDa in terms of molecular weight Y represents a monovalent group containing a biologically active substance, Z represents a monovalent group containing a fluorescent dye, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight. ^a1 is a fluorescently labeled PEGylated bioactive substance represented by the following formula: ^a1 is bonded to any one of the three nitrogen atoms of —N ₃ —. A method for producing the PEGylated bioactive substance according to claim 3, wherein the formula (II-b):
(In the formula, Z represents a monovalent group containing a fluorescent dye, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) Fluorescent dye-containing PEG compound and the following formula (III):
(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 is a divalent C _{1 to} C ₁₂ carbon atom which may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Hydrogen group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), Y is a biologically active substance Is reacted with a cyclic acetylene compound represented by formula (Ib) in physiological conditions (in aqueous solution, at room temperature and in the absence of a copper catalyst). A method for producing a fluorescently labeled PEGylated bioactive substance, comprising synthesizing a bioactive substance. Formula (II-a '):
(Wherein R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, and n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight). The deoxyfluoroPEG compound according to claim 5, wherein F in the formula (II-a ′) is ¹⁸ F. Formula (II-b):
(In the formula, Z represents a monovalent group containing a fluorescent dye, R ^a1 represents a divalent C _{1 to} C ₆ hydrocarbon group, and n represents an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) Fluorescent dye-containing PEG compound. Formula (II-c):
(In the formula, R ^h1 is substituted with a monovalent C _{1 to} C ₁₂ hydrocarbon group which may be substituted with a halogen atom, or a C _{1 to} C ₄ organic group which may contain a hetero atom or a halogen atom. phenyl groups optionally, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon radical, n is an integer in the range of 1kDa~40kDa molecular weight terms.) sulfonylated PEG compound represented by. A method for producing a sulfonylated PEG compound according to claim 8, which is represented by the following formula (II-c-1):
(Wherein R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), a diazo transfer reagent sulfonyl azide compound, Is reacted in a solvent to give the following formula (II-c-2):
(Wherein R ^a1 and n have the same ^{meanings as} described above), and then the obtained compound represented by the formula (II-c-2) is reacted with a sulfonylating reagent in a solvent. A method for producing a sulfonylated PEG compound, comprising synthesizing a sulfonylated PEG compound represented by the formula (II-c). It is a manufacturing method of the deoxyfluoro PEG compound of Claim 6, Comprising: following formula (II-c):
(In the formula, R ^h1 is substituted with a monovalent C _{1 to} C ₁₂ hydrocarbon group which may be substituted with a halogen atom, or a C _{1 to} C ₄ organic group which may contain a hetero atom or a halogen atom. An optionally substituted phenyl group, R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight, and ^A deoxyfluoroPEG compound represented by the above formula (II-a ′) labeled with [ ¹⁸ F] is synthesized by reacting with an ¹⁸ F] labeled fluorinating reagent in a solvent. Compound production method. A method for producing a fluorescent dye-containing PEG compound according to claim 7, wherein the following formula (II-b-1):
(Wherein R ^a1 is a divalent C ₁ -C ₆ hydrocarbon group, n is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight) and this formula (II-b- Fluorescence characterized by synthesizing a fluorescent dye-containing PEG compound represented by the formula (II-b) by reacting with a fluorescent dye having a functional group that reacts with the amino group of the compound represented by 1) A method for producing a dye-containing PEG compound. Formula (III):
(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^c1 represents a hydrogen atom or a fluorine atom, X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or —R ^d1 (OCH ₂ CH ₂ ) _m R ^d2 — (R ^d1 is a divalent C _{1 to} C ₁₂ carbon atom which may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m. Hydrogen group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight), Y is a biologically active substance A cyclic acetylene compound represented by the formula: Formula (III-1):
(Wherein R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom, R ^c1 and R ^c2 each independently represent a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or -R ^d1 (OCH ₂ CH ₂ ) _m R ^d2- (R ^d1 may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m . C ₁ -C ₁₂ hydrocarbon group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, and m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) A cyclic acetylene compound represented by: It is a manufacturing method of the cyclic acetylene compound of Claim 13, Comprising: following formula (III-1-1):
(Wherein R ^{b1 to} R ^b10 each independently represents a hydrogen atom or a fluorine atom, R ^e1 represents a divalent C _{1 to} C ₅ hydrocarbon group), and a cyclic acetylene compound represented by the following formula (III- 1-2):
(In the formula, R ^c1 and R ^c2 are each independently a hydrogen atom or a fluorine atom, R ^c3 is a C _{1 to} C ₈ hydrocarbon group or —R ^d3 (OCH ₂ CH ₂ ) _m R ^d4 — (R ^d3 is divalent) C _{1 to} C ₈ hydrocarbon group or OCH ₂ CH ₂ , R ^d4 may have an amide group, m is a divalent C _{1 to} C ₆ hydrocarbon group, m is in the range of 1 kDa to 40 kDa in terms of molecular weight OR ^c4 represents a leaving group that is eliminated by the reaction with the amino group of the fluorescent dye-containing PEG compound represented by (III-1) above.) Then, a method for producing a cyclic acetylene compound, which comprises synthesizing a fluorescent dye-containing PEG compound represented by the formula (III-1). It is a manufacturing method of the cyclic acetylene compound of Claim 12, Comprising: following formula (III-1):
(Wherein R ^{b1 to} R ^b10 each independently represent a hydrogen atom or a fluorine atom, R ^c1 and R ^c2 each independently represent a hydrogen atom or a fluorine atom, and X represents a divalent C _{1 to} C ₁₂ hydrocarbon group or -R ^d1 (OCH ₂ CH ₂ ) _m R ^d2- (R ^d1 may have an amide group or a carbamate group which may be formed with an oxygen atom of (OCH ₂ CH ₂ ) _m . C ₁ -C ₁₂ hydrocarbon group, R ^d2 is a divalent C ₁ -C ₆ hydrocarbon group optionally having an amide group, and m is an integer in the range of 1 kDa to 40 kDa in terms of molecular weight.) And a biologically active substance having a functional group that reacts with the maleimide group of the cyclic acetylene compound represented by the formula (III-1) to react with the above-described formula (III). A method for producing a cyclic acetylene compound, comprising synthesizing a cyclic acetylene compound represented by the formula: A method for non-invasively and quantitatively analyzing the pharmacokinetics of a PEGylated bioactive substance labeled with [ ¹⁸ F] F according to claim 1 in real time by positron tomography (PET).   A method for noninvasively and quantitatively analyzing the pharmacokinetics of the fluorescently labeled PEGylated bioactive substance according to claim 3 in real time by a fluorescence detection method.